Evidence map›Paper›PMID 42367811›Full record

ArticleFrontiers in immunology2026

Tislelizumab-induced distal renal tubular acidosis presenting with life-threatening hypokalemia: a case report.

Jiaju Xu, Lidong Qin, Ping Wang, Zhen Liu, Lili Yang, Hongwei Zhang, Yanqiu Wang, Jiao Gao, Meishu Zhao, Kaili Zhang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiaju Xu *Department of Medical Oncology, Tai'an City Central Hospital, Tai'an, Shandong, China.
Lidong Qin *Department of Medical Oncology, Tai'an City Central Hospital, Tai'an, Shandong, China.
Ping WangDepartment of Medical Oncology, Tai'an City Central Hospital, Tai'an, Shandong, China.
Zhen LiuDepartment of Medical Oncology, Tai'an City Central Hospital, Tai'an, Shandong, China.
Lili YangDepartment of Medical Oncology, Tai'an City Central Hospital, Tai'an, Shandong, China.
Hongwei ZhangDepartment of Medical Oncology, Tai'an City Central Hospital, Tai'an, Shandong, China.
Yanqiu WangDepartment of Medical Oncology, Tai'an City Central Hospital, Tai'an, Shandong, China.
Jiao GaoDepartment of Medical Oncology, Tai'an City Central Hospital, Tai'an, Shandong, China.
Meishu ZhaoDepartment of Medical Oncology, Tai'an City Central Hospital, Tai'an, Shandong, China.
Kaili ZhangDepartment of Medical Oncology, Tai'an City Central Hospital, Tai'an, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) affecting multiple organs. Distal renal tubular acidosis (dRTA) as a renal irAE is exceedingly rare, often delaying diagnosis due to nonspecific symptoms. A 63-year-old man with stage IIIA lung squamous cell carcinoma developed recurrent nausea and vomiting after three cycles of nab-paclitaxel/carboplatin combined with tislelizumab. Laboratory evaluation revealed profound metabolic acidosis (CO

Indexed as

Acidosis, Renal TubularHypokalemiaImmune Checkpoint InhibitorsLung NeoplasmsHumansMaleMiddle AgedImmune Checkpoint Inhibitorsdistal renal tubular acidosishypokalemiaimmune checkpoint inhibitorsimmune-related adverse eventstislelizumab

Identifiers

PMID42367811
PMCPMC13294038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.